News

NIAID to test new yellow fever vaccine


 

References

The National Institute of Allergy and Infectious Diseases (NIAID) has initiated a phase I clinical trial of an investigational vaccine designed to protect against yellow fever virus.

According to an NIAID statement, the study will evaluate whether an experimental vaccine developed by the pharmaceutical manufacturer Bavarian Nordic is “safe, tolerable and has the potential to prevent yellow fever virus infection.”

Courtesy Wikimedia Commons/Muhammad Mahdi Karim/Creative Commons License

Bavarian Nordic’s experimental yellow fever vaccine, called MVA-BN-YF, is based on the company’s proprietary MVA-BN platform, which uses an attenuated version of the Modified Vaccinia Ankara (MVA) virus as a vaccine vector to carry yellow fever virus genes into the body. Bavarian Nordic says that more than 7,600 people, including 1,000 who are immunocompromised, have been safely vaccinated with MVA-BN–based vaccines.

The NIAID statement noted that prior studies have suggested that combining MVA-BN with ISA 720, an experimental immune-boosting adjuvant, induces a strong immune response after a single dose of vaccine. One goal of the study will be to assess whether two doses of unadjuvanted vaccine or a single dose of ISA 720 adjuvanted vaccine could provide protection against yellow fever.

NIAID said the placebo-controlled, double-blinded clinical trial will enroll 90 healthy men and women aged 18-45 years who have never been infected with a flavivirus. Participants will be divided into six groups: One will receive the currently licensed yellow fever vaccine (15 participants) and five groups (15 participants each) will receive the investigational Bavarian Nordic vaccine, either with or without an adjuvant. The investigational vaccine will be administered intramuscularly while the licensed yellow fever vaccine will be administered subcutaneously. Trial participants will receive one or two doses of vaccine or placebo, separated by a month.

According to NIAID’s statement, the multisite trial will be conducted by NIAID-funded Vaccine and Treatment Evaluation Units at the University of Iowa, Iowa City, and Saint Louis (Mo.) University. The Emory Vaccine Center in Decatur, Ga., will assist in evaluating data.

Yellow fever infection usually causes fever, back pain, headache, nausea, vomiting, fatigue, and weakness, but roughly 15% of infected patients develop severe disease manifested as jaundice, hemorrhage, and shock, resulting in potentially fatal kidney, liver, or heart conditions.

The current yellow fever vaccine can produce severe adverse complications, such as neurologic side effects, multiple organ system dysfunction and death, and thus cannot be given to infants, the elderly, pregnant women, and those with compromised immune systems. More than 105 million people in Africa have been vaccinated against yellow fever since 2006, according to the World Health Organization (WHO), but a new outbreak of the disease has caused an estimated 84,000-170,000 severe illnesses and 29,000 to 60,000 deaths in 2013.

For more details about the trial, visit the National Institutes of Health Clinical Trials website.

rpizzi@frontlinemedcom.com

On Twitter @richpizzi

Recommended Reading

Motivational interviewing for HPV vaccination well accepted by doctors
MDedge Infectious Disease
Coadministering a combined MMRV vaccine with MenC vaccine is immunogenic
MDedge Infectious Disease
Influenza: A vaccine we love to hate
MDedge Infectious Disease
Approximately 9 million U.S. children, teens are vulnerable to measles infection
MDedge Infectious Disease
Zika virus RNA detected in serum beyond previously estimated time frame
MDedge Infectious Disease
NIH launches trial of Zika vaccine candidate
MDedge Infectious Disease
Combo MenC vaccine loses effectiveness after 5 years
MDedge Infectious Disease
Extended pneumococcal vaccination schedule boosts early immunity for preemies
MDedge Infectious Disease
HPV vaccination provides protection for immunocompromised children
MDedge Infectious Disease
Two-dose HPV vaccines at younger age are noninferior to standard three-dose vaccine
MDedge Infectious Disease